Last updated: October 2026

Votoplam (PTC518) is an oral huntingtin-lowering treatment candidate being developed for Huntington’s disease.

Current status

Its clinical program remains investigational and continues to be evaluated in clinical trials. It is not FDA approved, and timing, eligibility, safety, effectiveness, availability, and cost remain uncertain.

For the newest coverage across the HD treatment pipeline, visit What’s Happening in HD Treatment.